KRAS and colorectal carcinoma: In addition, GSEA revealed that KRAS mutant CRC cells (DLD‐1‐KRASG13D and Hke3‐KRASWT/13D+) have significant enrichment of ‘YAP1 driven gene signature’ (Fig. S6A,B; Table S3).